Five Prime Therapeutics Inc. (NASDAQ:FPRX) fell 3% on Thursday . The company traded as low as $44.67 and last traded at $44.84, with a volume of 174,044 shares trading hands. The stock had previously closed at $46.25.

A number of equities research analysts have recently commented on the stock. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a report on Sunday, May 8th. Zacks Investment Research cut shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, April 20th. Jefferies Group reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a report on Sunday, May 8th. Leerink Swann reaffirmed an “outperform” rating and issued a $58.00 target price (up from $45.00) on shares of Five Prime Therapeutics in a report on Monday, August 8th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $48.00 target price on shares of Five Prime Therapeutics in a report on Thursday, May 19th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $52.33.

The stock has a market cap of $1.22 billion and a price-to-earnings ratio of 5.10. The stock has a 50-day moving average price of $46.55 and a 200 day moving average price of $41.37.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.07. The firm had revenue of $9.23 million for the quarter, compared to analyst estimates of $6.38 million. Five Prime Therapeutics’s revenue for the quarter was up 46.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.45) earnings per share. Equities research analysts predict that Five Prime Therapeutics Inc. will post ($2.37) EPS for the current year.

In related news, Director Peder Jensen sold 12,195 shares of the firm’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $49.50, for a total transaction of $603,652.50. Following the completion of the sale, the director now directly owns 12,195 shares of the company’s stock, valued at approximately $603,652.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director William R. Ringo sold 500 shares of the firm’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $50.77, for a total transaction of $25,385.00. Following the sale, the director now directly owns 500 shares of the company’s stock, valued at $25,385. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Five Prime Therapeutics stock. RS Investment Management Co. LLC purchased a new position in Five Prime Therapeutics Inc. (NASDAQ:FPRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 511,170 shares of the company’s stock, valued at approximately $21,214,000. RS Investment Management Co. LLC owned approximately 1.86% of Five Prime Therapeutics as of its most recent filing with the SEC.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.